MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ofid/ofag319

Медицинская библиотека · Open forum infectious diseases · 2026

RESPIRE Score: Derivation and Validation of a New Risk Score for Prediction of Community-acquired Pneumonia Caused by Resistant Pathogens.

Pelagatti Lorenzo, De Marco Martina, Bosco Emma, Catalucci Tullio, Gilardoni Michele, Mangani Francesca, Spinicci Michele, Bartoloni Alessandro, Rossolini Gian Maria, Nazerian Peiman, Vanni Simone

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Community-acquired pneumonia (CAP) remains a leading cause of infectious mortality worldwide. The increasing prevalence of multidrug-resistant (MDR) pathogens challenges the established empirical antibiotic therapy schemes. This study aimed to derive and validate a clinical score (RESPIRE) to identify CAP-MDR patients.

METHODS

We conducted an observational study in a setting of medium-high multidrug-resistant (MDR) endemicity. The primary outcome was the derivation of a clinical score predicting MDR-CAP. A retrospective derivation cohort (January 2022-December 2023) including adult patients hospitalized with microbiologically confirmed CAP by culture on respiratory samples was used for score derivation. A prospective cohort (January 2024-December 2025) including adult patients with the same clinical features was used for score validation.

RESULTS

The derivation cohort included 275 patients (mean age 68.3 years), with an MDR prevalence of 30.1% (n = 83). The RESPIRE score assigns 1.5 points for recent hospitalization and prior antibiotic use, and 1 point each for enteral feeding, poor functional status, and residence in long-term care facilities (maximum 6 points). A cutoff ≥ 2 showed optimal performance in predicting CAP-MDR (AUROC 0.85; 95% CI 0.80-0.91), outperforming other scores except DRIP. Validation in 141 patients (39% MDR) confirmed an AUROC of 0.88 (95% CI 0.74-0.89) showing better performance compared to other diagnostic models.

CONCLUSIONS

The RESPIRE score outperformed HCAP criteria and other clinical scores in predicting CAP-MDR. Its implementation in protocols could support antimicrobial stewardship for empiric treatment of cases of CAP presenting at the Emergency Department. A multicenter validation is warranted to confirm the performance of the RESPIRE score.

TRIAL REGISTRATION NUMBER: NCT07425561.

Для цитирования: Pelagatti Lorenzo, De Marco Martina, Bosco Emma, Catalucci Tullio, Gilardoni Michele, Mangani Francesca, Spinicci Michele, Bartoloni Alessandro, Rossolini Gian Maria, Nazerian Peiman, Vanni Simone. RESPIRE Score: Derivation and Validation of a New Risk Score for Prediction of Community-acquired Pneumonia Caused by Resistant Pathogens.. Open forum infectious diseases. 2026. DOI: 10.1093/ofid/ofag319.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.